The use of PD-L1 cancer cell expression as a biomarker for PD-1/PD-L1 inhibitor response has attracted attention; however, its accuracy in this context, if used alone, is questionable (Patel and Kurzrock, 2015). This evidence concerns the gene PDCD1 and cancer.